GH Secretagogues
CJC-1295 DAC
← Back to Library
Limited / unverified FDA safety flag Limited / unverified GH Axis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 2, 5, 10 mg
Dosing window: Anytime
Receptor / target: GHRH
Properties: GH Secretagogue
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 300 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 3-4 | 500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 5-6 | 750 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 7-8 | 1000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 9-10 | 1250 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 11-12 | 1500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 13-14 | 1750 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 15-16 | 2000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 5-8 | 1000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 9-12 | 1500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 13-16 | 2000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 3-4 | 750 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 5-6 | 1000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 7-8 | 1250 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 9-10 | 1500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 11-12 | 2000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 13-14 | 2500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 15-16 | 3000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.
Independent evidence
Independent safety notes: FDA lists CJC-1295 among withdrawn nominated bulk substances with potential significant safety risks, limited clinical data, and serious adverse events reported.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer or history of malignancy: sustained GH and IGF-1 elevation accelerates cell proliferation; contraindicated in any actively growing tumor. Limited / unverified
- High risk of tumor growth: subjects with pre-cancerous conditions or elevated cancer biomarkers. Limited / unverified
- Active acromegaly or conditions involving excess endogenous GH or IGF-1: additive hypersomatotrophism. Limited / unverified
- Uncontrolled diabetes mellitus or significant insulin resistance: continuous GH elevation meaningfully increases insulin resistance; DAC's persistent hormonal profile is more problematic than pulsatile approaches. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Disruption of the hypothalamic-pituitary axis: pituitary adenoma, cranial radiation history, or post-surgical pituitary dysfunction. Limited / unverified
- Concurrent use with CJC-1295 No DAC, sermorelin, tesamorelin, or HGH 191aa: direct GHRH receptor competition or redundant GH axis overstimulation. Limited / unverified
- Concomitant high-dose glucocorticoid therapy: blunts pituitary GH response and inhibits IGF-1. Limited / unverified
- Severe carpal tunnel syndrome: GH-mediated fluid retention worsens median nerve compression. Limited / unverified
- Pregnancy: safety not established. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity to CJC-1295 DAC or any formulation excipients. Limited / unverified
- Pediatric use in children with closed growth plates. Limited / unverified
Side effects (limited evidence)
- Water retention and peripheral edema: the most frequently reported adverse effect; GH-mediated sodium and fluid retention is more persistent and pronounced with DAC than with No DAC due to continuous GH elevation. Limited / unverified
- Head rush and transient facial flushing: present but typically milder than with No DAC due to the absence of a sharp GH peak. Limited / unverified
- Joint stiffness and arthralgia: GH-mediated periarticular fluid accumulation; common, particularly in wrists, hands, and knees. Limited / unverified
- Tingling or numbness in extremities (paresthesia): from GH-related fluid shifts compressing peripheral nerves. Limited / unverified
- Carpal tunnel syndrome: sustained GH elevation can produce or exacerbate median nerve compression. Limited / unverified
- Fatigue or lethargy: more diffuse than with No DAC; related to sustained rather than pulsatile GH effects. Limited / unverified
- Headache: less acute than No DAC but present. Limited / unverified
- Increased appetite: modest orexigenic GH effects. Limited / unverified
- Vivid dreams: GH elevation during sleep phases. Limited / unverified
- Insulin resistance: continuous rather than pulsatile GH exposure has more significant impact on insulin sensitivity; monitor fasting glucose, particularly in subjects with metabolic risk factors. Limited / unverified
- Elevated fasting blood glucose: secondary to GH-mediated insulin resistance; monitor throughout cycle. Limited / unverified
- Pituitary downregulation: risk with DAC is somewhat higher than No DAC due to continuous GHRH-R stimulation; strict 4-week washout is required. Limited / unverified
- Slow side effect clearance post-cycle: albumin-bound DAC depot persists for 2+ weeks after the last injection; side effects do not resolve immediately upon stopping. Limited / unverified
- Injection site irritation: localized redness, swelling, or discomfort. Limited / unverified
- Antibody formation: rare; small percentage of subjects may develop anti-peptide antibodies with long-cycle use. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: